DrugMCTS: a Drug Repositioning Framework Combining Multi-Agent, RAG and Monte Carlo Tree Search
Zerui Yang, Yuwei Wan, Siyu Yan, Yudai Matsuda, Tong Xie, Bram Hoex, Linqi Song · 2025
Read DrugMCTS: a Drug Repositioning Framework Combining Multi-Agent, RAG and Monte Carlo Tree Search by Zerui Yang, Yuwei Wan, Siyu Yan, Yudai Matsuda, Tong Xie, Bram Hoex, Linqi Song (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2507-07426.txt.
Introduction
Zerui Yang and co-authors present DrugMCTS, a framework that finds new uses for old drugs by letting language model agents search like players in a game tree. Models alone reason only from what they memorized, while plain retrieval dumps facts without strategy. The framework fields five specialist agents that fetch and weigh molecular and protein evidence, guided by retrieval from curated databases.
Monte Carlo tree search steers the hunt: promising reasoning branches get explored more deeply, and feedback prunes the rest. On the DrugBank and KIBA benchmarks, the system recalled substantially more true drug-target links than general chatbots or standard deep learning baselines, and its answers held up more robustly across runs. The authors credit the structure: collaboration between agents, grounded retrieval, and search with feedback. They pitch the design as a template for language models doing science where the facts live outside the model.
Catalog record
| CREATOR | Zerui Yang, Yuwei Wan, Siyu Yan, Yudai Matsuda, Tong Xie, Bram Hoex, Linqi Song |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2507-07426
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
DrugMCTS: a Drug Repositioning Framework Combining Multi-Agent, RAG and Monte Carlo Tree Search Zerui Yang, Yuwei Wan, Siyu Yan, Yudai Matsuda, Tong Xie, Bram Hoex, Linqi Song Abstract Abstract Recent advances in large language models have demonstrated considerable potential in scientific domains such as drug repositioning. However, their effectiveness remains constrained when reasoning extends beyond the knowledge acquired during pretraining. Conventional approaches, such as fine-tuning or retrieval-augmented generation, face limitations in either imposing high computational overhead or failing to fully exploit structured scientific data. To overcome these challenges, we propose DrugMCTS, a novel framework that synergistically integrates RAG, multi-agent collaboration, and Monte Carlo Tree Search for drug repositioning. The framework employs five specialized agents tasked with retrieving and analyzing molecular and protein information, thereby enabling structured and iterative reasoning. Extensive experiments on the DrugBank and KIBA datasets demonstrate that DrugMCTS achieves substantially higher recall and robustness compared to both general-purpose LLMs and deep learning baselines. Our results highlight the importance of structured reasoning, agent-based collaboration, and feedback-driven search mechanisms in advancing LLM applications for drug repositioning. Contact: [email protected] 1 Introduction Large language models (LLMs) have demonstrated remarkable capabilities across a wide range of domains, including question answering, logical reasoning, and knowledge-intensive tasks such as mathematics and code generation. These models are increasingly being explored for applications in scientific fields, particularly in drug discovery [ 33 ] . However, when confronted with problems that lie beyond their pre-training knowledge or inherent reasoning abilities, such as predicting novel drug-target interactions, their performance may fall short of expectations [ 38 ] . As general-purpose large models gain traction in scientific domains, fine-tuning on domain-specific datasets has emerged as a common approach [ 36 , 27 ] . However, this method faces several well-recognized limitations. Fine-tuning is computationally expensive and typically domain-specific, making it inefficient and often impractical for extending to new scientific areas. Furthermore, given the dynamic nature of scientific knowledge, maintaining up-to-date models requires continual retraining, which increases computational overhead and risks catastrophic forgetting [ 19 ] . These challenges hinder the scalability and long-term utility of fine-tuning in real-world scientific applications. To address the drawbacks of fine-tuning, retrieval-augmented generation (RAG) has emerged as a promising alternative [ 35 ] . By leveraging external agents to retrieve relevant information from literature and databases, RAG enhances the reasoning capabilities of LLMs without requiring model updates [ 3 ] . This makes it particularly suitable for dynamic domains such as drug discovery. Despite its advantages, RAG faces notable limitations. Scientific data can be broadly categorized into structured scientific data and unstructured general-purpose text [ 39 ] . Existing RAG systems often prioritize the latter due to better compatibility with LLMs [ 23 ] , overlooking the richness of structured data such as molecular structures and protein sequences. For example, drug-target interaction tasks frequently exclude structural information, relying solely on knowledge graphs or text [ 14 ] , which compromises both prediction reliability and interpretability. Some methods incorporate domain-specific models to interpret scientific data [ 11 , 17 ] , but this reintroduces fine-tuning-related limitations. When inputs deviate from training distributions, performance can drop sharply—for instance, drug-target interaction models may lose over 20% accuracy on unseen molecule-protein pairs [ 31 ] . General-purpose data also presents challenges. It often contains noise or errors [ 10 ] , and LLMs may inadvertently discard useful content due to limited contextual understanding. For instance, long-context models are known to suffer from the “lost in the middle” [ 16 ] phenomenon (Figure 1 ), where information located in the middle of a long input sequence is more likely to be forgotten or overlooked [ 16 ] , leading to incomplete or inaccurate reasoning. Moreover, current approaches typically lack feedback loops, treating drug discovery as a one-shot task rather than an iterative process [ 33 , 4 , 6 ] , which limits robustness and adaptability. Figure 1 : When the document relevant to the query appears in the middle of the retrieved document sequence, the model’s performance can even fall below that of the baseline closed-book setting [ 16 ] . To address the aforementioned limitations, we propose DrugMCTS , a novel drug repositioning algorithm based on RAG, multi-agent collaboration, and Monte Carlo Tree Search (MCTS) [ 2 ] . DrugMCTS is designed to overcome the challenges posed by computationally expensive fine-tuning, underutilization of structured scientific data, model brittleness in out-of-distribution scenarios, and the lack of iterative feedback mechanisms. Our system comprises five specialized agents: • Retrieval Agent: Identifies and gathers structurally similar molecules from external scientific databases. While this is the first retrieval step in the pipeline, subsequent agents also incorporate retrieval mechanisms to augment the model’s input with task-relevant scientific knowledge. By leveraging external sources without modifying model parameters, these retrieval-based actions collectively mitigate the limitations of static knowledge and the high cost of fine-tuning. • Molecule-Analysis Agent: Receives a dictionary containing the physicochemical and structural properties of the query molecule and its candidates, obtained from scientific APIs (e.g., RDKit, PubChem). This agent then summarizes the input into a concise natural language description, making the information more accessible to LLMs. • Molecule-Selection Agent: Filters retrieved molecules based on pharmacophore integrity and drug-likeness, effectively eliminating low-relevance or noisy inputs that could compromise model performance. This filtering step also helps mitigate the “lost in the middle” phenomenon. • Interaction-Analysis Agent: Analyzes drug-target interaction mechanisms by extracting structured protein data (e.g., pocket features from PDB files via PLIP) and enriching it with natural language summaries from literature. This transformation enables general LLMs to reason over biological structures that they cannot natively parse. • Decision Agent: Integrates all upstream outputs—including molecular properties, interaction analyses, and supporting texts—and makes final predictions about likely protein targets. It serves as the final reasoning step informed by the entire multi-agent pipeline. Moreover, the incorporation of MCTS enables the framework to operate with a feedback-driven mechanism, iteratively refining its decision path. This allows the system to explore multiple reasoning trajectories and prioritize more promising nodes based on reward signals, thereby improving both robustness and decision quality over time. With the guidance of our framework, the lightweight Qwen2.5-7B-Instruct model [ 26 ] achieves performance surpassing Deepseek-R1 [ 7 ] , GPT-4o-mini [ 9 ] and domain-specific deep learning models on benchmark tasks. Notably, this is accomplished without any domain-specific fine-tuning. We further conduct ablation studies demonstrating that removing any component of our pipeline leads to a performance drop of 1–10%, underscoring the necessity of each module. To facilitate future research and ensure reproducibility, the code and data processing pipeline for DrugMCTS will be released upon publication at: https://github.com/yaoge777/DrugMCTS Our main contributions include: a. We introduce an end-to-end drug repositioning framework that enables Qwen2.5-7B-Instruct to outperform much larger models such as Deepseek-R1, without requiring any fine-tuned domain-specific model. The method leverages external structured and textual knowledge sources to boost reasoning and decision-making capabilities. b. By incorporating MCTS, our framework introduces a feedback mechanism that enables iterative refinement of decisions, autonomous filtering of noisy inputs, and robust identification of high-value evidence—addressing the lack of adaptability in current one-shot inference systems. c. We propose a systematic data processing pipeline (Figure 2 ) that transitions from structured scientific data to hybrid